Mucous Gland Adenoma of the Lung: A Neoplastic Counterpart of Mucinous Bronchial Glands.


Journal

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
ISSN: 1530-0285
Titre abrégé: Mod Pathol
Pays: United States
ID NLM: 8806605

Informations de publication

Date de publication:
06 2023
Historique:
received: 26 01 2023
revised: 20 03 2023
accepted: 29 03 2023
medline: 26 6 2023
pubmed: 8 4 2023
entrez: 7 4 2023
Statut: ppublish

Résumé

Mucous gland adenoma (MGA) is a rare benign tumor that usually arises in the proximal airway and consists of mucus-secreting cells resembling bronchial glands. Here, we report 2 cases of MGAs and describe their morphologic, immunohistochemical, and molecular profiles in comparison with 19 pulmonary tumors of 5 other histologic types with mucinous cells (invasive mucinous adenocarcinoma, mucoepidermoid carcinoma, mixed squamous cell and glandular papilloma, bronchiolar adenoma/ciliated muconodular papillary tumor, and sialadenoma papilliferum). Two MGAs were found in 1 male patient and 1 female patient, located in the bronchus and trachea, respectively. One MGA was examined by RNA sequencing, and no putative driver mutations (including BRAF, KRAS, and AKT1 mutations) or gene fusions were identified. In another case of MGA, V600E mutations of BRAF and E17K mutations of AKT1 were not detected by allele-specific real-time PCR or digital PCR, respectively. However, a gene expression analysis revealed that the MGA presented a specific RNA expression profile with multiple genes enriched in the salivary gland. The gene expression of NKX3.1 was significantly higher in the MGA case in comparison to normal control lungs (P < .001). We then examined NKX3.1 immunohistochemistry for 2 MGAs and 19 tumors of 5 other histologic types. NKX3.1 was positive in MGA (2/2, 100%), whereas all constituent cells, including mucinous cells, were negative for NKX3.1 in other histologic types (0%, 0/19). In normal lung tissue, NKX3.1 was positive for mucinous acinar cells of the bronchial glands. In conclusion, the gene expression profile, taken together with the histologic similarity between MGA and bronchial glands, and the preferred location of the tumors (proximal airways with submucosal glands) suggest that MGA is a neoplastic counterpart of mucinous bronchial glands. NKX3.1 immunohistochemistry can be a sensitive and specific ancillary marker that distinguishes MGA from other histologic mimics.

Identifiants

pubmed: 37028599
pii: S0893-3952(23)00087-X
doi: 10.1016/j.modpat.2023.100182
pii:
doi:

Substances chimiques

Proto-Oncogene Proteins B-raf EC 2.7.11.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

100182

Informations de copyright

Copyright © 2023 United States & Canadian Academy of Pathology. Published by Elsevier Inc. All rights reserved.

Auteurs

Eiichi Sasaki (E)

Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Japan; Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan. Electronic address: sasakia1es@gmail.com.

Katsuhiro Masago (K)

Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Japan.

Yoshihito Kogure (Y)

Department of Respiratory Medicine, National Hospital Organization Nagoya Medical Center, Nagoya, Japan; Department of Medical Oncology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.

Shiro Fujita (S)

Department of Respiratory Medicine, Kobe Central Hospital, Kobe, Japan.

Akari Iwakoshi (A)

Department of Respiratory Medicine, National Hospital Organization Nagoya Medical Center, Nagoya, Japan; Department of Pathology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.

Hiroaki Kuroda (H)

Department of Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.

Toyonori Tsuzuki (T)

Department of Surgical Pathology, Aichi Medical University, Nagakute, Japan.

Koji Tsuta (K)

Department of Pathology, Kansai Medical University, Hirakata, Japan.

Hirokazu Matsushita (H)

Division of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Nagoya, Japan.

Masahide Oki (M)

Department of Respiratory Medicine, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH